University of Arizona, Phoenix announce plans for new 245,000 square foot Bioscience Project for the Phoenix Biomedical Campus.
New Biosciences Partnership Building on Docket Pending Regents Approval
University of Arizona, Phoenix announce plans for new 245,000 square foot Bioscience Project for the Phoenix Biomedical Campus.
New Biosciences Partnership Building on Docket Pending Regents Approval
Second White Paper Reviews Proposals Made in the President’s Council of Advisors on Science and Technology 2012 Report on Propelling Innovation – Health Subcommittee Schedules Hearing on PCAST for May 20 Continue reading
Intensive training focuses on brain tumor research and neuroscienceContinue reading
Company: Ulthera, Inc.
Position: Human Resources Generalist
Job Description:
Ulthera is continuing to grow and has an immediate need for a Generalist with experience in Recruiting.
We would strongly prefer someone who has worked in the healthcare segment and/or someone who has worked in an environment with very little direction/process (we are in late stage start-up so people have to be able to find their own answers and just “make it work”).
The pace at Ulthera is incredibly fast with project prioritization being a required skill based on too much to do and not enough time being a standard scenario. Our purpose-driven culture dictates the need for someone who is kind, ethical and very sharp.
This should be someone who people easily connect with and confide in while still being process oriented enough to get every spreadsheet and task completed meticulously.
It’s a tall order, it always is when you are looking for the best!
Contact Ulthera if you know of anyone who might be a fit and feel free to pay this forward and pass it on!
Who to contact: Stacie Mallen s.mallen@ulthera.com OR Leticia Gastelum l.gastelum@ulthera.com
Career site: careers.ultherapy.com/
Insys Therapeutics Reports First Quarter 2014 Results
$41.6 Million in Net Revenue Marks Fifth Consecutive Quarter of Revenue Growth; Three-for-Two Stock Split Increases Shares Outstanding to 34.2 Million SharesContinue reading
Scientists have shown new genetic evidence that could strengthen the link between the role of dietary fats with colon cancer progression.Continue reading
CE Mark Gives SynCardia Systems, Inc. Control over Last Critical Component for SynCardia Heart ManufacturingContinue reading
Clinical Coordinator/Technical Writer
VisionGate Corporation
275 N. Gateway Dr. Phoenix, AZ 85034
VisionGate produces the Cell-CT™, the world’s first 3D cellular imaging device based upon optical projection tomography, which renders cells with sub-micron, isometric resolution. Based on 3D images of cells from sputum, VisonGate aims to improve patient health with the world’s first, non-invasive, diagnostic test for early lung cancer detection: LuCED™. VisionGate is expanding its team in Phoenix that will carry the development and commercialization of its products forward.
Position Summary
VisionGate is currently commercializing its LuCED test for early detection of lung cancer. We are also partnering with several institutions locally and internationally who will supply study specimens that will be used to evaluate the LuCED test. Development of other tests based on the Cell-CT are being considered or are in progress. To facilitate our development and clinical programs we seek to add a staff member who will coordinate these clinical studies. Responsibilities will also involve creation of clinical study protocols and reports, abstracts for publications, and other documentation required in a regulated environment. The position will report to the VisionGate CTO and may develop into a management role. Some travel may be required.
Roles and Responsibilities
Training and Experience
To apply contact Michael Meyer, meyer@visiongate3d.com
IT Support Engineer
VisionGate Corporation
275 N. Gateway Dr. Phoenix, AZ 85034
VisionGate produces the Cell-CT™, the world’s first 3D cellular imaging device based upon optical projection tomography, which renders cells with sub-micron, isometric resolution. Based on 3D images of cells from sputum, VisonGate aims to improve patient health with the world’s first, non-invasive, diagnostic test for early lung cancer detection: LuCED™. VisionGate is expanding to carry the development and commercialization of its products forward.
Position Summary
VisionGate is currently commercializing its LuCED test for early detection of lung cancer. Development of other tests based on the Cell-CT are being considered or are in progress. To facilitate commercialization of our tests and manage our research IT environment, we seek to add a part-time staff member who will help manage and grow our IT Infrastructure.
Roles and Responsibilities
Training and Experience
To apply contact Rahul Katdare, katdare@visiongate3d.com